CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced CEO John Climaco's participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami. A video of the presentation will be available for on-demand viewing for registered attendees. CNS is focused on developing novel treatments for brain and central nervous system cancers, including their lead drug candidate, Berubicin, which crosses the blood-brain barrier. The company is also advancing the WP1244 drug technology, showcasing promising preclinical results against various cancers.
- Participation in H.C. Wainwright Global Investment Conference enhances visibility.
- Berubicin is the first anthracycline shown to cross the blood-brain barrier.
- WP1244 shows high uptake in brain and significant antitumor activity.
- None.
HOUSTON, May 24, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will be participating at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.
A video webcast of Mr. Climaco's presentation is now accessible for viewing on-demand for those registered for the event and will be available on the Events page in the Investors section of the Company's website (www.cnspharma.com). The webcast replay will be archived for 90 days following the event.
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-presentation-at-the-hc-wainwright-global-investment-conference-301553649.html
SOURCE CNS Pharmaceuticals, Inc.
FAQ
What is CNS Pharmaceuticals participating in on May 23-26, 2022?
What is Berubicin and its significance?
What does WP1244 target?
Where can I watch CNS Pharmaceuticals' conference presentation?
